Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into phase 2. The Waltham, Massachusetts-based company already unveiled ...

Because tracheal tumors are rare, few institutions have had the opportunity to gain experience regarding this type of neoplasm, and, consequently, treatment is provided exclusively at some specialized ...